DAWN
NASDAQ HealthcareDay One Biopharmaceuticals, Inc. - Common Stock
Biotechnology
Day One Biopharmaceuticals, Inc., a commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral and brain-penetrant type II rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It is also developing DAY301, a PTK7 targeted ADC composed of a novel humanized anti-PTK7 immunoglobulin G1 monoclonal antibody conjugated with a topoisomerase I inhibitor via a highly stable and hydrophilic modified valine-alanine (VA) cleavable linker for the treatment of patients with advanced solid tumors; and Emi-Le, an antibody-drug conjugate that targets B7- H4 conjugated to an auristatin anti-tubulin payload as a component of a proprietary linker-payload platform developed by Mersana Therapeutics that is in Phase 1 clinicla trial for the treatment of breast cancer, ovarian cancer, endometrial cancer, and adenoid cystic carcinoma (ACC). Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.
�� 市场数据
| 价格 | $21.47 |
|---|---|
| 成交量 | 2,194,576 |
| 市值 | 2.22B |
| 贝塔系数 | -1.750 |
| RSI（14日） | 61.5 |
| 200日均线 | $10.43 |
| 50日均线 | $17.39 |
| 52周最高 | $21.49 |
| 52周最低 | $5.63 |
| Forward P/E | -502.69 |
| Price / Book | 5.01 |
🎯 投资策略评分
DAWN 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🐋 Institutional Whale (42/100) — 此策略 大盘、机构级别股票.
评分最低的策略： 🔪 Falling Knife (6/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 DAWN in your text
粘贴任何文章、记录或帖子 — 工具将提取 DAWN 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.